Viavi Solutions EVP Paul McNab Sells 11,032 Shares for $429,917

Viavi Solutions EVP and Chief Marketing & Strategy Officer Paul McNab sold 11,032 shares at a weighted average $38.97, realizing about $429,917 and reducing his directly held stake by 30% to 25,639 shares worth about $993,511. The sale was McNab's third in 2026 and follows Viavi's 216% one-year total return, suggesting potential profit-taking. Viavi generated $1.5 billion of trailing-12-month revenue, up 40% year over year, but recorded a $30.4 million net loss as it increased investment to address AI-related network-testing demand.

Analysis

The sale is not, by itself, a high-conviction fundamental signal: the retained position remains meaningful and the absolute dollar value is immaterial versus VIAV's daily liquidity. The more relevant implication is positioning. After a 216% return, VIAV is priced as an AI/network-capex beneficiary despite still needing to demonstrate that incremental revenue converts into durable operating profit rather than elevated R&D, inventory, and working-capital requirements.

Near term, a single-officer sale can create a modest technical air pocket if momentum holders treat it as confirmation of a crowded trade; that is more likely over days than quarters. Over the next 1-3 months, the stock needs bookings, backlog, and gross-margin evidence that demand is extending beyond episodic telecom lab/test cycles. A revenue beat without operating-margin leverage would likely compress the premium sales multiple, particularly given the company remains loss-making on a trailing basis.

The non-obvious competitive risk is that AI infrastructure spending may favor production-network vendors and optical-component suppliers more directly than test-and-measurement vendors once initial deployment and qualification phases mature. Conversely, sustained higher network complexity raises recurring assurance demand and could support a structurally higher service/software mix over 6-18 months; this requires disclosure of recurring revenue and customer concentration, neither of which is established by the filing.

Consensus may overread both sides: insider selling is weak evidence, but the article's valuation comfort is also unsupported because a sales multiple is not cheap when earnings are negative and the end-market cadence is cyclical. Treat VIAV as an earnings-quality trade, not an insider-flow trade.

Key Decisions for Investors

• No standalone trade on the Form 4. Maintain or initiate only a small VIAV watch position pending the next earnings release; require order growth and forward operating-margin guidance to validate the AI-capex thesis.
• For momentum exposure, use a defined-risk tactical hedge: buy 1-3 month VIAV put spreads only if shares fail to hold the post-filing level and telecom/order commentary weakens. The thesis is multiple compression from slowing bookings or absent margin leverage; exit if guidance rises and the stock reclaims prior highs.
• Relative-value watch: long NVDA versus short VIAV only after evidence that AI spending is concentrating in compute rather than network-test budgets. This is not actionable without comparable valuation, beta, and next-quarter booking data; use it as a catalyst-monitoring framework.
• Falsify the cautious view if VIAV reports accelerating backlog/bookings, expanding gross margin, and credible timing to sustained profitability at the next earnings print; those metrics would support retaining premium-multiple exposure over 6-18 months.